Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
ANRITSU, 19% Increase in Net Income for The Current Fiscal Year
6754 ANRITSU CORPORATION 【IFRS】
Earnings ReportANRITSU CORPORATION <6754> [TSE Prime] announced its financial results (based on IFRS) after the market closed on April 25th (15:30). The consolidated net income for the fiscal year ending March 2025 increased 20.6% from the previous period to 9.25 billion yen. In the fiscal year ending March 2026, the profit is expected to grow by 18.8% to 11 billion yen.
In the most recent three-month period, from January to March (4Q), the consolidated net income grew 16.1% from the same period last year, reaching 4.35 billion yen. The operating profit margin jumped from 11.9% in the same period last year to 17.8%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 110,919 | 11,746 | 12,438 | 9,272 | 70.0 | 40 | Apr 28, 2023 | IFRS |
Mar, 2024 | 109,952 | 8,983 | 9,951 | 7,675 | 58.3 | 40 | Apr 25, 2024 | IFRS |
Mar, 2025 | 112,979 | 12,124 | 12,737 | 9,257 | 70.4 | 40 | Apr 25, 2025 | IFRS |
YoY | +2.8% | +35.0% | +28.0% | +20.6% | +20.8% |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2025 Guidance | 115,000 | 11,000 | 11,000 | 8,300 | 63.6 | 40 | Apr 25, 2024 | IFRS |
Mar, 2025 Results | 112,979 | 12,124 | 12,737 | 9,257 | 70.4 | 40 | Apr 25, 2025 | IFRS |
Revision Rate | -1.8% | +10.2% | +15.8% | +11.5% | +10.8% |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Sep, 2024 | 53,309 | 3,576 | 3,381 | 2,237 | 17.0 | 20 | Oct 30, 2024 | IFRS |
Apr - Sep, 2025 Guidance | ー | ー | ー | ー | - | 20 | Apr 25, 2025 | IFRS |
YoY | - | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2024 | 109,952 | 8,983 | 9,951 | 7,675 | 58.3 | 40 | Apr 25, 2024 | IFRS |
Mar, 2025 | 112,979 | 12,124 | 12,737 | 9,257 | 70.4 | 40 | Apr 25, 2025 | IFRS |
Mar, 2026 Guidance | 123,000 | 15,000 | 15,000 | 11,000 | 86.0 | 40 | Apr 25, 2025 | IFRS |
YoY | +8.9% | +23.7% | +17.8% | +18.8% | +22.1% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jan - Mar, 2024 | 32,171 | 3,824 | 4,315 | 3,751 | 28.5 | 11.9 | Apr 25, 2024 | IFRS |
Apr - Jun, 2024 | 25,229 | 622 | 1,254 | 716 | 5.4 | 2.5 | Jul 31, 2024 | IFRS |
Jul - Sep, 2024 | 28,080 | 2,954 | 2,127 | 1,521 | 11.6 | 10.5 | Oct 30, 2024 | IFRS |
Oct - Dec, 2024 | 27,531 | 2,843 | 3,866 | 2,666 | 20.2 | 10.3 | Jan 30, 2025 | IFRS |
Jan - Mar, 2025 | 32,139 | 5,705 | 5,490 | 4,354 | 33.1 | 17.8 | Apr 25, 2025 | IFRS |
YoY | -0.1% | +49.2% | +27.2% | +16.1% | +16.3% |
Related Articles
TOHO LAMAC, Jan-Mar (1Q) Ordinary Profit Turns to Loss
Kawagishi Bridge Works, First Half Ordinary Profit Revised Upward to an Unexpected 8% Increase
ADVANTEST, 11% Increase in Net Income, Update Record High for Second Consecutive Term
Astellas Pharma, Last Fiscal Year's Net Income Unexpectedly Increases, 2.6 times Increase in Net Income for The Current Fiscal Year, Dividend Raised by 4 yen
TORICO, Last Fiscal Year Net Income Loss Widened in Downward Revision
ZENITAKA, Last Fiscal Year Ordinary Profit Revised Upward to an Unexpected 2% Increase, Dividend Revised Upward by 20 yen
TORII PHARMA, Jan-Mar (1Q) Ordinary Profit Increases by 59%
SEMITEC, Last Fiscal Year Ordinary Profit Revised Upward to an Unexpected 5% Increase
TOWNNEWS-SHA, Jul-Mar (Cumulative 3Q) Ordinary Profit Decreases by 15%, Jan-Mar Ordinary Profit Decreases by 16%
INTELLEX, The Current Fiscal Year Ordinary Profit Revised Upward by 18%, Dividend Revised Upward by 12 yen